[go: up one dir, main page]

WO2002051865A3 - Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih - Google Patents

Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih Download PDF

Info

Publication number
WO2002051865A3
WO2002051865A3 PCT/FR2001/003957 FR0103957W WO02051865A3 WO 2002051865 A3 WO2002051865 A3 WO 2002051865A3 FR 0103957 W FR0103957 W FR 0103957W WO 02051865 A3 WO02051865 A3 WO 02051865A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv virus
inducing antibodies
proteinic
antigens inducing
antibodies neutralising
Prior art date
Application number
PCT/FR2001/003957
Other languages
English (en)
Other versions
WO2002051865A2 (fr
Inventor
Veronique Barban
Original Assignee
Aventis Pasteur
Veronique Barban
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0016986A external-priority patent/FR2818648B1/fr
Application filed by Aventis Pasteur, Veronique Barban filed Critical Aventis Pasteur
Priority to AU2002219290A priority Critical patent/AU2002219290A1/en
Publication of WO2002051865A2 publication Critical patent/WO2002051865A2/fr
Publication of WO2002051865A3 publication Critical patent/WO2002051865A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention a pour objet un antigène protéique de formule P-E-S dans laquelle: P désigne une protéine ou un peptide porteur ou un fragment en dérivant; E désigne un bras espaceur de 2 à 25 acides aminés, constitué principalement de glycine, proline ou alanine; S une séquence peptidique spécifique, ledit antigène étant capable d'induire des anticorps neutralisants contre des isolats primaires du VIH ainsi que son utilisation dans un vaccin anti VIH.
PCT/FR2001/003957 2000-12-22 2001-12-12 Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih WO2002051865A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002219290A AU2002219290A1 (en) 2000-12-22 2001-12-12 Proteinic antigens inducing antibodies neutralising hiv virus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR00/16986 2000-12-22
FR0016986A FR2818648B1 (fr) 2000-12-22 2000-12-22 Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
US26481901P 2001-01-26 2001-01-26
US60/264,819 2001-01-26

Publications (2)

Publication Number Publication Date
WO2002051865A2 WO2002051865A2 (fr) 2002-07-04
WO2002051865A3 true WO2002051865A3 (fr) 2002-09-12

Family

ID=26212802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/003957 WO2002051865A2 (fr) 2000-12-22 2001-12-12 Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih

Country Status (2)

Country Link
AU (1) AU2002219290A1 (fr)
WO (1) WO2002051865A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964554B2 (en) * 2004-09-03 2011-06-21 Amateraspharma Inc. Polypeptide that binds anti-histone H1 antibody
US20180303740A1 (en) * 2015-10-26 2018-10-25 Basf Se Oral care products and methods comprising hlps
JP2018536644A (ja) * 2015-10-26 2018-12-13 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ハイドロキシアパタイト結合タンパク質を含む口腔ケア製品及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035194A2 (fr) * 1996-03-21 1997-09-25 President And Fellows Of Harvard College Procede de criblage enantiomere et compositions pour ce procede
WO1999066046A1 (fr) * 1998-06-12 1999-12-23 Aventis Pasteur Mimotopes du virus hiv

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035194A2 (fr) * 1996-03-21 1997-09-25 President And Fellows Of Harvard College Procede de criblage enantiomere et compositions pour ce procede
WO1999066046A1 (fr) * 1998-06-12 1999-12-23 Aventis Pasteur Mimotopes du virus hiv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOMSGAARD A ET AL.: "Improved Humoral and Cellular Immune Responses Against the gp120 V3 Loop of HIV-1 Following Genetic Immunization with a Chimeric DNA Vaccine Encoding the V3 Inserted into the Hepatitis B Surface Antigen", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 47, 1998, pages 289 - 295, XP002181537 *

Also Published As

Publication number Publication date
WO2002051865A2 (fr) 2002-07-04
AU2002219290A1 (en) 2002-07-08

Similar Documents

Publication Publication Date Title
GB9007024D0 (en) Novel vaccine
KR910016343A (ko) 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프
IL102687A0 (en) Method for enhancing immunogenicity
WO1995029193A3 (fr) Antigenes du melanome
ATE366313T1 (de) Antigene peptide aus neisseria
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
MXPA04000597A (es) Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
EP2298793A3 (fr) Fragments polypeptidiques du virus de l'hépatite E, composition vaccinale contenant lesdits fragments, agents diagnostics et leurs applications
WO1996021734A3 (fr) Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
GB9401987D0 (en) Modified nucleic acid
NZ535908A (en) HIV regulatory and auxilliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
DK0491628T3 (da) Lipopeptider inducerende cytotoksiske T-lymfocytter og deres anvendelse som vacciner
WO2003015702A3 (fr) Epitopes du virus de l'immunodeficience humaine de type 1
WO2002051865A3 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
CA2521038A1 (fr) Polypeptide comprenant un motif d'adhesion cellulaire, un epitope de lymphocyte t et un epitope de lymphocyte b utilise pour induire la production d'anticorps
WO1997039029A3 (fr) Epitope antigenique du determinant a de l'antigene de surface de l'hepatite b et ses utilisations
WO2004056316A3 (fr) Vaccins contre la proteine tat de vih servant a generer des anticorps neutralisants
AU6839598A (en) Antigenic structural peptide, antigenic and immunogenic compounds and uses for detecting, preventing and treating an hcv infection
WO2007129218A3 (fr) Peptides utilisés dans la détection ou l'induction de la production d'anticorps contre le papillomavirus humain, la protéine l1 ou les peptides de ladite protéine
WO2001093804A3 (fr) Conjugues du virus de l'hepatite c
WO2005062871A3 (fr) Peptides d'epitopes lineaires tat et conjugues lies a utiliser dans des compositions et des dosages therapeutiques
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
Ivanoff et al. Human immunodeficiency virus antigen.
TH44158A3 (th) สายพันธุ์ไวรัสตับอักเสบชนิด b ที่เหนี่ยวนำให้เกิดขึ้นโดยวัคซีนและการใช้งานของสายพันธุ์ดังกล่าว

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP